Phase 1b/2 Open-Label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and PK and PD Profiles of SNS-595 Injection in Combination With Cytarabine in Patients With Relapsed or Refractory AML.

Trial Profile

Phase 1b/2 Open-Label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and PK and PD Profiles of SNS-595 Injection in Combination With Cytarabine in Patients With Relapsed or Refractory AML.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2015

At a glance

  • Drugs Vosaroxin (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 20 Mar 2015 According to the Sunesis Pharmaceuticals media release, results from this study is published in Haematologica.
    • 06 Jun 2012 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
    • 10 Nov 2010 Updated data were presented at the Chemotherapy Foundation Symposium XXVIII, according to a Sunesis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top